Oct 12, 2025 6:10 PM Eastern Daylight Time Six oral presentations highlight Signatera's expanding role across solid tumors, including definitive predictive data in adjuvant bladder cancer AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate includes six ...